All kinds of pharmaceutical services.
The Analytical Expertise Center of the Ministry of Health conducted inspections in February 2024 in Baku city, with 1 planned and 1 unplanned inspection, as well as in other cities and districts of the republic, with 23 planned and 12 unplanned inspe...
See more
"In accordance with the amendments to the Law of the Republic of Azerbaijan "On Medicinal Products" (hereinafter - the Law) No. 979-VIQD dated July 14, 2023, certain cases of refusal to grant permission for the import of medicinal products to the Rep...
See more
The Center for Analytical Expertise of the Ministry of Health conducted another training session on the "Monitoring and Tracking System for Medicines" for state medical institutions under the auspices of the Medical Territorial Divisions Management A...
See more
A new rule on the recognition of foreign (international) registration of medicinal products has been established in Azerbaijan. According to "Report", this was made possible by President Ilham Aliyev's approval of changes to the Law "On Medicines"...
See more
Guided by clauses 19 and 32 of Article 109 of the Constitution of the Republic of Azerbaijan, I make a decision to ensure the implementation of the Law of the Republic of Azerbaijan No. 979-VIQD dated July 14, 2023 "On Amendments to the Law of the Re...
See more
Idorsia Ltd announced that the European Commission (EC) has granted marketing authorisation for QUVIVIQ (daridorexant) for the treatment of adult patients with insomnia characterised by symptoms present for at least three months and considerable impa...
See more
In a recent interview, Rebecca Gomperts, MD, founder of Aid Access, highlighted plans to make abortion pills available as a weekly contraceptive. In an interview with Democracy Now, Rebecca Gomperts, MD, mentioned plans to make mifepristone, the a...
See more
Merck (NYSE:MRK) has announced that it will stop the Phase 3 LYNK-003 trial focused on Lynparza (olaparib) with or without bevacizumab for patients with unresectable or metastatic colorectal cancer. Two experimental arms in the trial, one focused on ...
See more
Astellas Pharma (TSE:4503) has revealed that the FDA has slapped a clinical hold on its Phase 1/2 FORTIS Pompe disease study after observing a serious adverse event (SAE) — peripheral sensory neuropathy — in a trial participant. Peripheral sensory...
See more
The therapy will be used for specific muscle invasive urothelial cancer patients Bristol Myers Squibb has announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination recommending Opdivo (n...
See more
Azərbaycanca 
Русский 
